2024
Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice
Thomas J, Schindler E, Gottschalk C. Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice. Journal Of Clinical Investigation 2024, 134: e182556. PMID: 39087472, PMCID: PMC11290958, DOI: 10.1172/jci182556.Peer-Reviewed Original ResearchConceptsBlocking CGRP signalingCGRP receptor componentsMigraine-like painCervical lymph nodesGap junction proteinPrimary headache disordersLymphatic vessel dysfunctionAcute migrainePharmacological blockadeLymph nodesHeadache disordersNeurological symptomsJunction proteinsCGRPLymphatic vesselsMeningeal lymphatic vesselsInducible knockoutVessel dysfunctionMigraineReceptor componentsHeadachePainPathophysiologyDysfunctionMice
2022
The Epidemiology of Primary Headache Disorders
Kopel D, Gottschalk C. The Epidemiology of Primary Headache Disorders. Seminars In Neurology 2022, 42: 449-458. PMID: 36104164, DOI: 10.1055/a-1942-6823.Peer-Reviewed Original ResearchConceptsPrimary headache disordersHeadache disordersCommon primary headache disorderHigher migraine prevalenceNumber 1 causeCommon headache disorderCause of disabilityBurden of migrainePopulation-based estimatesTension-type headacheAmerican Indian/Alaskan NativeAI/AN menChronic migrainePrevalence of stigmaMigraine prevalenceGlobal burdenClinical careEpidemiologic studiesMigraine incidenceMigrainePrevalence estimatesDisease StudyPrevalenceAlaskan NativesDisorders
2020
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministrationEptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache The Journal Of Head And Face Pain 2020, 60: 2220-2231. PMID: 33165938, PMCID: PMC7756794, DOI: 10.1111/head.14007.Peer-Reviewed Original ResearchConceptsEptinezumab 100Days/monthDay 1Chronic migrainePreventive efficacyCalcitonin gene-related peptideMonthly migraine daysPercentage of patientsPrevention of migraineGene-related peptideTreatment effectsMigraine preventive effectMigraine daysInitial dosePreventive effectEptinezumabWeek 1MigrainePatientsPlaceboSustained preventionMonoclonal antibodiesEfficacyMonthsNonsignificant results
2015
Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins
Schaefer SM, Gottschalk CH, Jabbari B. Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins. Toxins 2015, 7: 2615-2628. PMID: 26184313, PMCID: PMC4516932, DOI: 10.3390/toxins7072615.Peer-Reviewed Original ResearchConceptsChronic migraineBotulinum toxin injection therapyLarge healthcare costsBotulinum toxin therapyTreatment of migraineCommon neurological disorderToxin therapyInjection therapyPathophysiological mechanismsMigraine pathophysiologyHealthcare costsMigraineNeurological disordersAnimal dataBotulinum neurotoxinTherapyTreatmentInjection techniqueCurrent understandingMedicationsPathophysiology